December 18, 2013 | Israeli stem cell company Pluristem Therapeutics is moving forward with the agreement reached with Korean company CHA Bio & Diostech signed last June. The two companies have agreed on a strategic partnership which will also include a $10.4 million mutual investment via share swap.
Related posts
Israeli Animal Syringe Firm Unveils New Products For Fish Industry
September 10, 2024
Israeli Monitoring System For Seniors To Be Introduced In Europe
September 10, 2024
Israeli-Indian Osteoarthritis Therapy Gets FDA Fast Track Designation
September 09, 2024
Israeli Greentech Firm Expanding in US, Plans Waste 'Transformation'
September 08, 2024
Facebook comments